S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Janjigian
    Janjigian
  8. Jhanwar
    Jhanwar
  9. Tang
    Tang
  10. Clarkson
    Clarkson

Groups

  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Thoracic Oncology (45)
  10. Department of Pathology and Laboratory Medicine (43)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (255)
  3. Book Section (20)
  4. Review (16)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (280)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (5)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (635)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of rociletinib (CO-1686) in centrally confirmed T790M-positive and T790M-negative non-small cell lung cancer (NSCLC) patients (Pts)
    Meeting Abstract

    Sequist, L. V.; Goldman, J. W.; Wakelee, H.; Camidge, D. R.; Gadgeel, S.; Yu, H. A.; Varga, A.; Solomon, B.; Oxnard, G. R.; Ou, S. H. I.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Improvement in survival in patients with oral squamous cell carcinoma
    Meeting Abstract

    Krepper, M.; Amit, M.; Gil, Z.; Shah, J.; Rothamel, D.; Scheer, M.; Patel, S.; Zoller, J.
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia
    Journal Article

    Patel, A. B.; Solomon, A. R.; Mauro, M. J.; Ehst, B. D.
    Dermatology (2016)

    Fulltext@MSK | Save
  • Genetic testing awareness and attitudes among Latinos: Exploring shared perceptions and gender-based differences
    Journal Article

    Hamilton, J. G.; Shuk, E.; Arniella, G.; González, C. J.; Gold, G. S.; Gany, F.; Robson, M. E.; Hay, J. L.
    Public Health Genomics (2016)

    Fulltext@MSK | Save
  • Randomized phase 2 three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN plus EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R.; Hutson, T.; Glen, H.; Michaelson, M. D.; Molina, A.; Eisen, T.; Jassem, J.; Zolnierek, J.; Maroto, P.; Mellado, B.; more...
    Oncology Research and Treatment (2015)

    Fulltext@MSK | Save
  • Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study
    Meeting Abstract

    Krug, U.; Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E.; more...
    Oncology Research and Treatment (2015)

    Fulltext@MSK | Save
  • Treatment of refractory hairy cell leukemia by BRAF-inhibition
    Meeting Abstract

    Dietrich, S.; Pircher, A.; Andrulis, M. A.; Peyrade, F.; Wendtner, C. M.; Gaehler, A.; Follows, G.; Dyer, M.; Elter, T.; Zeiser, R.; more...
    Oncology Research and Treatment (2015)

    Fulltext@MSK | Save
  • Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin's lymphoma (iNHL) in idelalisib (IDELA) trials
    Meeting Abstract

    Stilgenbauer, S.; Barrientos, J.; Ghia, P.; Pagel, J.; Salles, G. A.; Sharman, J. P.; Gurtovaya, O.; Kim, Y.; Philip, B.; Zelenetz, A. D.
    Oncology Research and Treatment (2015)

    Fulltext@MSK | Save
  • Selective engagement of the RIG-I pathway synergizes with checkpoint blockade in cancer immunotherapy
    Meeting Abstract

    Heideager, S.; Kreppel, D.; Bscheider, M.; Wintges, A.; Bek, S.; Schmickl, M.; Fischer, J. C.; Lin, C. C.; Peschel, C.; Haas, T.; more...
    Oncology Research and Treatment (2015)

    Fulltext@MSK | Save
  • Generation of natural killer cell memory during viral infection
    Journal Article

    O'sullivan, T. E.; Sun, J. C.
    Journal of Innate Immunity (2015)

    Fulltext@MSK | Save